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Abstract: Rationale: A reduced response to inhaled corticosteroids (ICS) has been reported in smoking asthmatic patients 
but the effects of other medications remain to be evaluated in this population. 
Subjects and Methods: We evaluated the effects of a combined therapy of budesonide 200 μg twice daily and formoterol 6 
μg twice daily compared with budesonide 200 μg twice daily alone on asthma control questionnaire (ACQ), asthma 
quality of life questionnaire (AQLQ- Juniper), pulmonary function and airway inflammation, in a cross-over randomized 
double-blind study with treatment periods of two months separated by a one-month wash-out period. Seventeen smoking 
and 22 non-smoking patients not using inhaled corticosteroids with slightly uncontrolled mild asthma completed the 
study. 
Results: ACQ and AQLQ scores were similar in both groups at baseline and improved similarly after treatments. 2-
agonist use was higher in smokers, regardless of the treatment received (p=0.03), as it was on baseline (p=0.003). 
Smokers treated with budesonide/formoterol showed an increase in the number of asthma episodes (intercurrent asthma 
symptoms, p=0.016) while non-smoking subjects had a significant decrease in these episodes (p=0.009). No difference 
was found between smokers and non-smokers in regard to post-treatment airway inflammatory parameters. 
Conclusions: No significant differences were found between smoking and non-smoking subjects with mild asthma in 
regard to clinical changes in asthma control, pulmonary function and airway inflammation following a 2-month treatment 
period with budesonide or the association of budesonide and formoterol for a period of 2 months. This should be further 
explored in larger groups of subjects. 
Keywords: Asthma, formoterol, budesonide, smoking. 
INTRODUCTION 
  Smoking is associated with a significant morbidity and 
mortality but unfortunately this habit is still common 
worldwide [1, 2]. In Canada, about one out of four asthmatic 
subjects currently smokes, a prevalence similar to the general 
population [3, 4] despite observations of an increased asthma-
related morbidity and decline in pulmonary function in 
smokers [5-7]. Frequency of respiratory symptoms has been 
reported to be higher in smoking asthmatic patients and 
asthma to be more difficult to control than in non-smokers 
[8-10]. There are increasingly available data on the influence 
of smoking on pulmonary function of asthmatic subjects and 
their response to various medications but the optimal 
treatment of asthma in smokers is still to be determined [9]. 
  Cigarette smoking has been associated with a reduction 
in the efficacy of inhaled corticosteroid (ICS) treatment in 
mild asthma, possibly in relation with a change in the type of 
underlying airway inflammation, with an associated increase 
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in the number of neutrophils [11-13]. The comparative 
influence of 2-agonists or other asthma medications remain 
however to be documented in this population. 
  Current guidelines suggest that in mild to moderate 
steroid-naive subjects ICS are the first choice as initial 
maintenance therapy although if asthma remains uncont-
rolled with a low dose of this type of medication, the 
addition of an inhaled long-acting 2-agonist (LABA), 
ideally in the same inhaler, is considered as a preferred 
option [14, 15]. However, we need to determine if this 
therapeutic strategy is appropriate in smoking asthmatic 
subjects, in assessing their response to ICS or combination 
therapy compared to non-smokers. 
  In this study, we therefore evaluated the effects of a 
combination of budesonide and formoterol compared to 
budesonide alone on asthma control, asthma-related quality 
of life, pulmonary function and airway inflammation in mild 
smoking asthmatic subjects not using inhaled corticosteroids 
or any other anti-inflammatory medication. 
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METHODS 
Study Design 
  This was a cross-over double-blind randomized study 
with treatment periods of two months separated by a wash-
out period of one month. After a 2-week run-in period on 
short-acting inhaled bronchodilator on demand, both groups 
of subjects (smokers and non-smokers) were randomized to 
receive either budesonide (Pulmicort
R), 200 μg one 
inhalation twice daily, or budesonide 200 μg and formoterol 
6 μg, (Symbicort
R), one inhalation twice daily for a period of 
2 months. Subjects were defined as non-smokers if they had 
not smoked in the last year and had less than two pack-years 
of smoking, while smokers currently smoked more than ten 
cigarettes/day and had more than five pack-years of smoking 
(mean: 10.9 ± 5.5 pack years). 
  During the run-in period, peak expiratory flows (PEF) 
were measured twice daily as well as daily symptoms and 
bronchodilator use, and recorded on a diary card. During the 
study period, these parameters were measured 14 days before 
each study visit. Asthma control questionnaires were 
administered at entry in the study (visit 1), and then before 
and after each treatment. 
  During the run-in period, a thoracic examination, a 
baseline methacholine challenge, bronchodilator response 
assessment and allergy skin prick test were performed. On 
each visit, asthma control parameters, expiratory flows and 
airway inflammation as assessed by induced sputum analysis 
were measured. 
  All subjects provided an informed consent and the study 
was approved by the institutional Ethic Committees (Institut 
universitaire de cardiologie et de pneumologie de Québec 
and Sacré-Coeur Hospital). 
Subjects 
Inclusion Criteria for All Groups 
1.  Age ranging 18-45 in order to minimise the 
possibility of including patients with smoking-
induced Chronic Obstructive Pulmonary Disease 
(COPD). 
2.  Good health apart from asthma as determined by 
history and physical examination. 
3.  Smoking habits  20 pack/years. 
4.  History consistent with asthma in accordance with the 
criteria proposed by the American Thoracic Society 
[16], showing an improvement in forced expiratory 
volume in one second (FEV1)  12 % from baseline 
ten minutes after receiving 400μg of salbutamol. 
5.  FEV1 >70% predicted value. 
6.  Asthma sub-optimally controlled according to the 
Canadian asthma consensus guidelines, while using 
only a short-acting 2-agonist on demand, but this 
condition had to be stable for at least 3 months before 
entering the trial. Patients should have required 
however no more than 3 doses of rescue medication 
per day (no more than 6 inhalations of salbutamol or 
3 of terbutaline) [15]. Nasal steroids not allowed 
except if they were kept at the same dose throughout 
the study. 
Exclusion Criteria 
1.  Subjects who were, in the opinion of the investigator, 
mentally or legally incapacitated thus preventing 
informed consent from being obtained. 
2.  Another pulmonary disorder than asthma or a co-
existing illness that may affect the tests required. 
3.  Pregnant or lactating women. 
4.  Subjects unable to perform the tests or with 
contraindications to the tests proposed. 
5.  History of upper respiratory tract infection in the last 
month. 
6.  Use of oral or inhaled corticosteroid in the last 6 
months. 
Measurements 
  Questionnaire and Asthma Control Assessment: A 
validated questionnaire, the Asthma Control Scoring System 
(ACSS) [17], and the Juniper et al. Asthma Control 
Questionnaire (ACQ) [18]
  were used to assess asthma 
control for the last week before each visit. A standardized 
quality of life questionnaire (AQLQ) was filled by the 
patient at each visit
 [19]. 
 Allergy  Skin  Tests: Skin prick tests were done with a 
battery of common airborne allergens. Atopy was defined as 
the presence of at least one positive (3 mm wheal or greater) 
response to allergens after ten minutes. 
 Spirometry:  Expiratory flows were measured from flow-
volume curves performed according to the American 
Thoracic Society (ATS) specifications [20]. Predicted values 
were from Knudson [21]. The FEV1 was calculated as the 
best of the three reproducible values. 2-agonist response 
was determined by administering four inhalations of 
salbutamol 100 g and then measuring spirometry 10 
minutes later. 
 Methacholine  Challenge: Methacholine responsiveness 
was measured using the tidal volume method [22]. Briefly, 
concentrations of methacholine up to 32 mg/ml were used. 
Response was expressed as the provocative concentration of 
methacholine inducing a 20% fall in FEV1 (PC20) 
methacholine. 
  Induced Sputum Analysis: Sputum was obtained with 
hypertonic saline according to the method described by Pin 
et al. and modified by Pizzichini et al., which involves 
inhaling increasing concentrations of saline (3, 4, and 5%) 
for seven minutes each through a mouthpiece without a 
valve or nose clip [23]. Two cytospins were prepared, dried 
and stained by DIFF Quik solutions (Dade Diagnostics, 
Aguada, USA) and a 400 non-squamous cell differential 
count was performed, including eosinophils, neutrophils, 
macrophages, lymphocytes and bronchial cells. The 
remaining cell suspension was spun at 500g for 10 min and 
the supernatant was aspirated and stored at minus 80ºC for 
Eosinophil Cationic Protein (ECP) and Myeloperoxydase 
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  Rescue Medication Use and Exacerbations: We 
evaluated  2-agonist need, number of awakenings due to 
asthma, and number of asthma episodes, defined as 
intercurrent asthma symptoms, during the last week of run-in 
and 2 weeks before each end of treatment. 
 Randomisation:  Patients were double blind randomised 
from an external randomisation code. 
 Sample  Size: We aimed to enrol 60 patients, 30 smokers 
and 30 non-smokers. We considered that the cross-over 
design would increase significantly the statistical power of 
such study and we believed that the cross-over period would 
be sufficient to avoid sufficient overlap of the previous 
treatment. We hypothesized that the improvement in asthma 
control as shown by the ACQ would be significantly greater 
in the smokers after treatment with budesonide/formoterol 
than after budesonide compared to non smokers. A 
difference of 0.5 in the ACQ score was considered as 
clinically significant. We considered that a group sample 
size of about 20 subjects in each group (33% drop out) 
would allow to achieve 80% power to detect a difference of 
0.6 in the ACQ between the smokers and the non smokers 
with estimated respective group standard deviations of 0.5 
and 1.0 and with a significance level (alpha) of 0.05 using a 
two-sided Mann-Whitney test since the data were likely to 
be non normally distributed. 
Analysis 
  The primary parameter was ACQ. Secondary parameters 
included ACSS and AQLQ scores, baseline FEV1 and PEF, 
2 use, episodes of awakenings, number of asthma episodes 
and total and differential cell counts, ECP and MPO in 
induced sputum. 
 
Table 1.  Subjects’ Characteristics 
 
  Smokers (n=17 )  Non-Smokers (n=22 )  p 
Age (y)  30.0 ± 5.8  29.1 ± 6.4  0.65 
Female/Male 11/6  16/6   
Atopy (%)  15 (88)  21 (95)   
Duration of asthma (y)  19.2 ± 9.6  15.9 ± 8.8  0.28 
N. pack-years of smoking   10.9 ± 5.5     
FEV1 (L)  3.2 ± 0.7  3.0 ± 0.7  0.31 
% pred  92.7 ± 16.7  85.1 ± 12.5  0.11 
FVC (L)  4.7 ± 1.0  4.0 ± 0.9  0.03 
% pred  116.1 ± 16.2  98.8 ± 13.9  0.001 
PEF am (L/min)  401.0 ± 65.4  417.3 ± 86.1  0.52 
PEF pm (L/min)  434.8 ± 70.1  432.2 ± 98.5  0.93 
PC20 mg/ml*  0.84 (0.51-1.38)  0.85 (0.54-1.32)  0.90 
2 use/week   8.2 ± 3.6   4.5 ± 3.6   0.003 
Awakenings/week  1.8 ± 2.9  1.4 ± 2.7  0.66 
Asthma episodes/week  8.6 ± 5.6  6.8 ± 3.3  0.21 
ACQ Score  2.0 ± 0.6  1.9 ± 0.7  0.77 
ACSS Score  
Clinical  70.0 ± 9.5  73.2 ± 11.6  0.36 
Physiological  84.7 ± 13.3  81.8 ± 20.4  0.62 
Inflammatory  69.3 ± 24.9  62.9 ± 25.8  0.50 
Global  74.9 ± 8.9  73.9 ± 13.0  0.77 
AQLQ Score 
Symptoms  4.4 ± 1.0  4.3 ± 1.0.  0.65 
Activities  5.6 ± 0.9  5.1 ± 1.2  0.16 
Emotion  5.1 ± 1.1  5.1 ± 1.3  0.91 
Stimuli  5.1 ± 1.2  5.1 ± 1.4  0.91 
Global  5.0 ± 0.8  4.8 ± 1.0  0.58 
Data are mean ± SD or otherwise mentioned. 
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  From subjects’ characteristics data, one-way ANOVA 
and Fisher’s exact test were used to analyze continuous and 
categorical variables respectively. All cell counts variables 
as well as PC20 were log-transformed to stabilize variance. 
Variables expressed in percentage were analysed using the 
sin
-1(
.) transformation. Statistical results from these 
parameters were expressed with transformed values. All data 
were analyzed using a cross-over design where each subject 
received two treatments (budesonide and budesonide/ 
formoterol) in one of the two sequences: budesonide, bude-
sonide/formoterol, and budesonide/formoterol, budesonide. 
In each sequence, the scatter plot of the change in each 
patient’s response over the two treatment periods showed 
high between-patient variability, suggesting defining the 
subjects as a random effect in the statistical model. Values 
before treatments were used as covariates as well as the 
comparisons between smoker and non-smoker subjects. The 
Kenward and Roger degree of freedom approximation was 
used as unbalanced settings occurred and this method has the 
advantage to produce the exact result. The normality 
assumption was verified with the Shapiro-Wilk test and the 
Brown and Forsythe's variation of Levene's test statistic was 
used to verify the homogeneity of variances. All assumptions 
were fulfilled. The results were considered significant with 
p-values < 0.05. The data were analyzed using the statistical 
package program SAS v9.1.3 (SAS Institute Inc., Cary, NC). 
RESULTS 
  We screened 51 smoking and 69 non-smoking 
consecutive asthmatic subjects from Institut universitaire de 
cardiologie et de pneumologie de Québec, Quebec City and 
Sacré-Coeur Hospital, Montreal (Canada) asthma clinics. Of 
them, 29 smokers (S) and 31 non-smokers (NS) fulfilled the 
inclusion criteria and were randomized. From this group, 17 
smokers and 22 non-smokers completed the study. Patients 
were withdrawn due to lost to follow-up (7S, 4NS), 
withdrawal of consent (2S, 1NS), adverse events (2S, 3NS) 
and non compliance (1S, 1NS). 
 
Baseline Subjects’ Characteristics 
  Baseline subjects’ characteristics are summarized in 
Table 1. The two groups were similar with regard to age, 
severity and duration of asthma. There were more women 
than men and most patients had long-standing asthma. 
Smokers had a mean (± SD) number of pack-years of 
cigarettes of 10.9 ± 5.5. Fifteen smokers (88%) and 21 non-
smokers (95%) were atopic. 
  Baseline ACQ, ACSS and AQLQ scores were not different 
between the two groups. On baseline, FEV1 and PC20 were 
similar between groups (p>0.05) but forced vital capacity 
(FVC) was higher in smokers (p=0.03). Number of asthma 
episodes per week were similar in both groups but smokers 
reported more frequent bronchodilator use (p=0.003). The 
numbers and % of cells found in induced sputum, were similar 
in both groups (p> 0.05). Data are reported in Table 2. 
Changes in Parameters Following Treatments 
Asthma Control 
  The ACQ scores assessed in the last week before each 
end of treatment were similar in smokers and non-smokers 
(p=0.23). In both groups there was no treatment effect on the 
changes observed (Table 3). 
  From the ACSS questionnaire, expressed as a percentage 
of optimal values for the last week of treatments, smokers 
had a lower global asthma control score than non-smokers 
(p=0.03) (poorer control, particularly of the inflammatory 
component). 
  In regard to the ACSS questionnaire clinical and 
physiological scores, results were similar in smokers 
compared with non-smokers (respective p values: 0.74, 
0.62). Regarding ACSS score on airway inflammation, 
smokers had a lower score, with a higher % of eosinophils in 
sputum (p=0.002). Treatment effect was similar in smokers 
and non-smokers (p=0.87). In both groups, subjects   
 
 
Table 2.  Baseline Cells Analysis of Sputum 
 
  Smokers (n=14)  Non-smokers (n=13)  p 
Total cells (x 10
6/g)  3.8 (2.3 – 11.4)  3.5 (0.7 – 14.4)  0.75 
Neutrophils (x 10
6/g) % 
1.4 (0.3 – 10.6) 
49 (11 – 93) 
0.6 (0 – 4.2) 
27.3 (0 – 82.3) 
0.12 
0.17 
Macrophages (x 10
6/g) % 
1.9 (0.7 – 3.5) 
43.3 (6.5 – 69.5) 
1.3 (0 – 10.4) 
58.5 (9.8 – 97.0) 
0.80 
0.23 
Lymphocytes (x 10
6/g) % 
0 (0 – 0.1) 
1.0 (0.2 – 3.5) 
0 (0 – 0.5) 
1.1 (0 – 5.5) 
0.39 
0.37 
Bronchial epithelial cells (x 10
6/g) % 
0.1 (0 – 0.1) 
1.8 (0 – 4.0) 
0 (0 – 0.3) 
0.8 (0 – 3.0) 
0.54 
0.28 
ECP (ng/ml)  
56.0  
(5.3 – 423.2) 
285.7 (23.5 - 1227.8) 
(n=7) 
0.20 
MPO (ng/ml) 
197.7  
(14.2 – 2004.1) 
176.5 (20.2 – 2034.8) 
(n=9) 
0.83 
Data are median (range). Influence of Budesonide and Budesonide/Formoterol on Asthma Control  The Open Respiratory Medicine Journal, 2010, Volume 4    55 
receiving budesonide/formoterol increased significantly their 
inflammatory score, reflecting a decrease in their eosinophils 
in sputum (p=0.045) (Table 3). 
 Regarding  2-agonist need assessed in the last 2 weeks 
before each end of treatment, smokers had a higher mean 
frequency of 2-agonist use compared with non-smokers 
(p=0.03) (Table 3). 
  Number of awakenings due to asthma assessed in the last 
two weeks before each end of treatment were similar in 
smokers and non-smokers (p=0.32). 
  Treatment effect was similar and non significant in 
smokers and non-smokers whatever the above parameters 
analysed. 
  Smokers showed a higher number of asthma episodes 
compared to non-smokers (p=0.04). Smokers treated with 
budesonide/formoterol having a significant increase in their 
number of asthma episodes (p=0.016) while non-smoking 
subjects showed a significant decrease in these episodes 
(p=0.009) (Table 3). 
Asthma Quality of Life Questionnaire 
  The mean global score of AQLQ questionnaire and 
various domains as symptoms, activities, emotions or 
stimulus were similar in smokers and non-smokers 
(respective p value: 0.58, 0.18, 0.25, 0.36, 0.21). Treatment 
effect was similar and non significant in smokers and non-
smokers (p>0.05) (Table 3). 
Pulmonary Function Tests 
  Post-treatment changes in FEV1, FVC, morning peak 
flow expiratory (PEF am) and night-time peak flow 
expiratory (PEF pm) were similar in smokers compared to 
non-smokers (respective p= 0.48, 0.64, 0.15, 0.23). 
Treatment effect was also similar in smokers and non-
smokers (respective p values 0.98, 0.80, 0.73, 0.88). 
However evening PEF were significantly higher in both 
groups using budesonide/formoterol (p=0.02) while other 
variables were similar (p>0.05) (Table 3). 
Airway Inflammation 
  The numbers and percentages of cells and markers found 
in induced sputum are reported in Table 4. Median (range) 
absolute sputum eosinophil, and lymphocyte counts, ECP 
and MPO were similar in smokers compared to non-smokers 
(respective p: 0.41, 0.51, 0.34, 0.32, 0.59. We found an 
increased number of macrophages in non-smokers (p=0.03)). 
No significant changes were found in the 2 groups using one 
or the other treatment (p>0.05) except for neutrophils. We 
found an increased number of neutrophils in sputum of the 2 
Table 3.  Treatment Responses to Pulmonary Function and Asthma Control 
 
Smokers Non-Smokers 
  Budesonide 
(n=17) 
Budesonide + 
Formoterol (n=17) 
p  Budesonide 
(n=22) 
Budesonide + 
Formoterol (n=22) 
p 
FEV1 % pred  96.1 ± 17.6  97.1 ± 17.7  0.91  93.2 ± 14.4  93.6 ± 12.5  0.85 
FVC % pred.   116.7 ± 16.3  116.3 ± 15.5  0.74  103.0 ± 19.4  102.5 ± 15.6  0.98 
PEFam
†  414 ± 72  430 ± 63  0.11  460 ± 101  467 ± 95  0.34 
PEFpm
†  429 ± 73  445 ± 61  0.11  464 ± 101  476 ± 96  0.08 
2 agonist use
†  6.9 ± 9.2  5.9 ± 5.2  0.12  2.7 ± 4.0  3.5 ± 5.1  0.63 
Awakening
†   1.9 ± 4.2  1.3 ± 1.9  0.27  0.8 ± 1.3  0.6 ± 1.3  0.50 
Asthma episodes
†  5.3 ± 5.6  7.2 ± 6.6  0.016  4.2 ± 4.8  2.5 ± 2.4  0.009 
ACQ Score
†  1.1 ± 0.7  1.2 ± 0.7  0.78  0.8 ± 0.6  0.9 ± 0.7  0.89 
ACSS Score
† 
Clinical  84.7 ± 14.2  98.8 ± 16.5  0.66  87.0 ± 11.0  84.5 ± 21.5  0.69 
Physiological  89.7 ± 14.2  91.2 ± 15.8  0.30  87.3 ± 14.5  89.1 ± 13.4  0.86 
Inflammatory  66.2 ± 21.2  75.0 ± 13.7  0.13  80.0 ± 21.4  84.6 ± 16.6  0.26 
Global  80.2 ± 8.9  81.9 ± 10.9  0.31  85.1 ± 10.5  86.7 ± 10.3  0.28 
AQLQ Score
†† 
Symptoms  5.6 ± 0.8  5.4 ± 0.8  0.78  6.0 ± 1.0  5.9 ± 1.0  0.62 
Activities  6.2 ± 0.6  6.1 ± 0.6  0.56  6.3 ± 0.6  6.3 ± 0.7  0.90 
Emotion  6.5 ± 0.5  7.0 ± 3.5  0.65  6.3 ± 0.7  6.3 ± 0.9  0.58 
Stimuli  5.9 ± 0.7  5.8 ± 0.8  0.87  6.1 ± 1.1  6.3 ± 0.7  0.42 
Global  6.0 ± 0.6  6.0 ± 1.0  0.99  6.2 ± 0.8  6.2 ± 0.7  0.84 
Data are mean ± SD. 
†Last 2 weeks of treatment. 
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groups when on budesonide/formoterol (p=0.04). Repre-
sentative measurements are shown on Table 4. 
DISCUSSION 
  It has been previously shown that adding a LABA to an 
ICS in asthmatic patients not optimally controlled with an 
ICS alone would improve significantly asthma control and 
reduce exacerbations, although there was no significant 
difference in most control parameters between ICS or 
ICS+LABA treatments in steroid-naïve mild asthma [24, 
25]. It has also been shown that smoking could impair 
response to ICS treatments, and that it may be related to a 
different type of airway inflammation or other mechanisms 
leading to a reduced response to corticosteroids, such as 
those involving histone decarboxylase [9, 26-28]. It was 
therefore of interest to determine the effects of ICS 
compared to ICS combined to a LABA in smoking 
compared to non-smoking asthmatic patients, as there are no 
studies up to now, looking specifically at this question. 
  In this study, we found that a group of smokers with a 
mean of about 11 pack/years of smoking had similar changes 
in the various parameters tested when compared to non-
smokers apart from a reduction in asthma episodes on 
combination therapy in non-smokers compared to smokers. 
This study could not find a difference in response to both ICS 
and combination therapy with ICS or LABA, between 
smokers and non-smokers although this may be different with 
heavier or very long duration of smoking; we also cannot 
exclude that this is due to an insufficient sample size. We did 
not include in the study, patients with more than 20 pack/years 
of smoking to avoid enrolling patients with COPD. Our 
patients had mild asthma and moderate smoking as we wanted 
to avoid including smoking-induced COPD. It is possible 
nevertheless that difference between treatments could have 
been found in more severe patients or heavier smokers. 
  Although previous studies on response to ICS in smokers 
were done in a relatively similar number of patients as in our 
study, and as we had a crossover study design, increasing the 
power of statistical analysis, it is possible that significant 
differences could have been found with a larger sample size 
[12]. Even if we cannot exclude a type II error, we can 
nevertheless considered this trial as a valid pilot project to 
obtain data that would help support further investigation on 
the differential response between smoking and non-smoking 
asthmatic patients. Our results suggest that there are no 
differences in the pattern of response of these two groups in 
regard to the treatments offered although it could be of 
interest to test a larger number of patients. 
  We previously reported that asthmatic smokers had more 
frequent respiratory symptoms and evidence suggesting early 
COPD-like changes such as High-Resolution Chest 
Tomography (HRCT) emphysema-like abnormalities, more 
marked airflow limitation, and lower lung diffusion capacity 
than non-smoking asthmatic patients [10]. Furthermore, 
increased numbers of neutrophils have been found in 
smokers in induced sputum [10, 12]. These two observations 
would suggest that smoking asthmatics would be less 
responsive to ICS although they may benefit more with a 
combination treatment with an ICS plus LABA. We could 
not confirm this possibility in our study, although in regard 
to respiratory symptoms, smokers were using their rescue 
bronchodilator more frequently than non-smokers. The 
similar response to ICS may be due to the lack of marked 
changes in the pattern of airway inflammation in these 
patients, with such degree of smoking. Indeed, in regard to 
airway inflammation, smokers had evidences of increased 
airway inflammation form ACSS scores, and seemed to have 
a lesser response to treatments in regard to the reduction in 
sputum eosinophils although this was not statistically 
significant. The increases in sputum neutrophils that were 
observed in both groups on combination therapy were not 
Table 4.  Treatment Responses of Cells and Markers in Sputum 
 
 Smokers  Non-Smokers 
  Budesonide 
(n= 15 ) 
Budesonide + 
Formoterol (n= 14 )  p  Budesonide 
(n= 14 ) 
Budesonide + 
Formoterol (n= 14 )  p 
Cells in Sputum 
Total cells (x 10
6/g)  1.8 (0.4-20.0)  2.5 (0.4-11.6)  0.74  2.5 (0.6-14.4)  3.1 (0.2-31.0)  0.45 
Eosinophils (x 10
6/g) % 
0 (0-0.5) 
2.3 (0-16.2) 
0 (0-0.1) 
0.6 (0-5.3) 
0.63 
0.16 
0 (0-0.4) 
0.8 (0-8.0) 
0 (0-1.1) 
1.6 (0-4.0) 
0.43 
0.56 
Neutrophils (x 10
6/g) % 
0.7 (0.1-18.7) 
29.0 (8.0-93.3) 
1.0 (0-10.4) 
51.5 (4.5-90.3) 
0.45 
0.52 
0.3 (0-6.9) 
14.8 (2.5-76) 
1.2 (0-16.2) 
29.9 (11-85) 
0.01 
0.12 
Macrophages (x 10
6/g) % 
1.2 (0.2-2.9) 
63.3 (4.5-83.3) 
1.5 (0.4-2.0) 
44.8 (8.3-88.0) 
0.50 
0.61 
1.5 (0.4-7.0) 
81.0 (15.3-94.0) 
1.7 (0.2-25.9) 
64.5 (12.5-86.5) 
0.37 
0.23 
Lymphocytes (x 10
6/g) % 
0 (0-0.1) 
1.3 (0-4.5) 
0 (0-0.1) 
0.6 (0-3.0) 
0.85 
0.30 
0 (0-0.3) 
1.4 (0-7.3) 
0.1 (0-0.2) 
1.8 (0-2.8) 
0.65 
0.74 
ECP (ng/ml)  41 (19- 459)  54 (7-3851)  0.74 
122 (5-370) 
n=8 
158 (40-1462) 
n=8 
0.52 
MPO (ng/ml)  187 (7-997)  163 (11-7674)  0.58 
103 (3-856) 
n=8 
36 (4-3879) 
n=9 
0.49 
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significant and difficult to explain. In smokers, it could have 
suggested an increased penetration of smoke into the 
airways, but this was also observed in non-smokers. 
  Further research is therefore needed to determine the 
comparative response to ICS, combination therapy between 
ICS and LABA and other agents according to the intensity of 
and duration smoking in asthmatic patients. 
  In conclusion, we found no significant difference 
between smoking and non-smoking asthmatic patients in 
regard to response to treatment with a budesonide or a 
combination of budesonide plus formoterol.  This study 
brings useful information that suggests that potential changes 
in medication responses should be further explored in large 
number of patients who are heavier smokers. 
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